In a latest note to investors, a research analyst has provided a rating update for the Healthcare company, Quipt Home Medical (QIPT – Research Report). Today, an analyst has provided a rating update for the Healthcare company, Quipt Home Medical (TSX: QIPT).
According to TipRanks.com, Quenneville is a 1-star analyst with an average return of -3.3% and a 29.9% success rate. Quenneville covers the Healthcare sector, focusing on stocks such as Cognetivity Neurosciences, Antibe Therapeutics, and Valeo Pharma.
Quipt Home Medical has an analyst consensus of Moderate Buy, with a price target consensus of C$11.75.
Based on Quipt Home Medical’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of C$60.28 million and GAAP net loss of C$1.03 million. In comparison, last year the company earned revenue of C$36.69 million and had a net profit of C$785K.
Protech Home Medical Corp provides in-home monitoring equipment, supplies and services to patients. The company’s services consist of Daily & Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea & PAP Treatment.
The company’s shares closed last Monday at C$6.80.
Read More on TSE:QIPT:
- Quipt Home Medical announces multi-state acquisition
- Quipt Announces Multi-State Acquisition Adding Approximately $9 Million in Annualized Revenues, and Anticipated $2 Million in Adjusted EBITDA Post Integration
- Quipt Home Medical reports Q2 revenue $60.3M, consensus $60.03M
- Quipt Home Medical Reports Strong Operational Performance With Record Third Quarter Fiscal 2023 Financial Results Posting Revenue Growth of 64% and Adjusted EBITDA Growth of 80%
- Is QIPT a Buy, Before Earnings?
